Annemieke Kok

Mrs. Annemieke Kok

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinical Nutrition
Verified
Journal Article
Closed access
AWAnna C.H. Willemsen
Anna C.H. Willemsen
AKAnnemieke Kok
Annemieke Kok
SKSander M.J. van Kuijk
Sander M.J. van Kuijk
LBLaura WJ Baijens
Laura WJ Baijens
RBRemco de Bree
Remco de Bree
AHAnn Hoeben
Ann Hoeben

29 July 2009 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
PDF file
CBC. H. S. B. Van Den Berg
C. H. S. B. Van Den Berg
TLT. J. W. Van De Laar
T. J. W. Van De Laar
AKAnnemieke Kok
Annemieke Kok
FZF. R. Zuure
F. R. Zuure
RCR. A. Coutinho
R. A. Coutinho
MPM. Prins
M. Prins
Summary.  The aim of this study was to gain insight in transmission routes of hepatitis C virus (HCV) infection among never‐injecting drug users (DU) by studying, incidence, prevalence, determinants and molecular epidemiology of HCV infection. From the Amsterdam Cohort Studies among DU, 352 never‐injecting DU were longitudinally tested for HCV antibodies. Logistic regression was used to identify factors associated with antibody prevalence. Part of HCV NS5B was sequenced to determine HCV genotype and for phylogenetic analyses, in which sequences were compared with those from injecting DU. HCV antibody prevalence was 6.3% and HCV incidence was 0.49/1000 PY. HIV‐positive status, female sex and starting injection drug use during follow‐up (a putative marker of past injection drug use), were independently associated with HCV prevalence. The main genotypes found were genotype 3a (50%) and 1a (30%). Phylogenetic analysis revealed that HCV strains in never‐injecting DU did not cluster together and did not differ from HCV strains circulating in injecting DU. We found a higher HCV prevalence in never‐injecting DU than in the general population. Phylogenetic analysis shows a strong link with the injecting DU population. The increased risk could be related to underreporting of injecting drug use or to household or sexual transmission from injectors to noninjectors. Our findings stress the need for HCV testing of DU who report never injecting, especially given the potential to treat HCV infection effectively.

11 August 2022 in European Journal of Cancer Care
Verified
Journal Article
Open access
AKAnnemieke Kok
Annemieke Kok
EPEllen Passchier
Ellen Passchier
AMAnne M. May
Anne M. May
Michiel Van den BrekelMichiel Van den Brekel
Michiel Van den Brekel
HJHarriet Jager-Wittenaar
Harriet Jager-Wittenaar
CSCaroline Speksnijder
Caroline Speksnijder
Chemoradiotherapy (CRT) for head and neck cancer (HNC) is associated with high toxicity that adversely affects physical functioning, body composition, fatigue, quality of life and treatment outcomes. Exercise interventions during treatment might counteract these negative effects. We therefore assessed the feasibility of an exercise programme for HNC patients during CRT. Forty patients were offered a tailored 10‐week endurance and resistance training with supervised and home‐based sessions. Feasibility endpoints were (1) adherence (main outcome): ≥60% attendance; (2) recruitment: ≥30%; (3) retention rate: ≥85% and (4) compliance rate: ≥60%. Physical performance, muscle strength, body composition, quality of life and fatigue were assessed pre‐ and post‐intervention. Overall adherence was 54%. The recruitment rate was 36%, and the retention rate was 65%. Compliance to the supervised intervention protocol was 66%. Statistically significant decreases were found in mean grip strength, fat‐free mass and clinically relevant deteriorations on several domains of quality of life, and fatigue subscales were found. We conclude that this exercise programme for HNC patients during CRT in its current form is feasible for only a minority of patients. We suggest adaptations to improve adherence and retention rates for a definitive multicentre trial. This study is registered at the Netherlands Trial Register (NTR7305), 6 June 2018, retrospectively registered.

1 January 2022 in Clinical Nutrition
Verified
Journal Article
Open access
AWAnna C.H. Willemsen
Anna C.H. Willemsen
AKAnnemieke Kok
Annemieke Kok
LBLaura W.J. Baijens
Laura W.J. Baijens
JBJan Paul de Boer
Jan Paul de Boer
RBRemco de Bree
Remco de Bree
AHAnn Hoeben
Ann Hoeben
Patients who receive chemoradiotherapy or bioradiotherapy (CRT/BRT) for locally advanced head and neck squamous cell carcinoma (LAHNSCC) often experience high toxicity rates interfering with oral intake, causing tube feeding (TF) dependency. International guidelines recommend gastrostomy insertion when the expected use of TF exceeds 4 weeks. We aimed to develop and externally validate a prediction model to identify patients who need TF ≥ 4 weeks and would benefit from prophylactic gastrostomy insertion. A retrospective multicenter cohort study was performed in four tertiary head and neck cancer centers in the Netherlands. The prediction model was developed using data from University Medical Center Utrecht and the Netherlands Cancer Institute and externally validated using data from Maastricht University Medical Center and Radboud University Medical Center. The primary endpoint was TF dependency ≥4 weeks initiated during CRT/BRT or within 30 days after CRT/BRT completion. Potential predictors were extracted from electronic health records and radiotherapy dose-volume parameters were calculated. The developmental and validation cohort included 409 and 334 patients respectively. Multivariable analysis showed predictive value for pretreatment weight change, texture modified diet at baseline, ECOG performance status, tumor site, N classification, mean radiation dose to the contralateral parotid gland and oral cavity. The area under the receiver operating characteristics curve for this model was 0.73 and after external validation 0.62. Positive and negative predictive value for a risk of 90% or higher for TF dependency ≥4 weeks were 81.8% and 42.3% respectively. We developed and externally validated a prediction model to estimate TF-dependency ≥4 weeks in LAHNSCC patients treated with CRT/BRT. This model can be used to guide personalized decision-making on prophylactic gastrostomy insertion in clinical practice.

4 February 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
AKAnnemieke Kok
Annemieke Kok
EPEllen Passchier
Ellen Passchier
AMAnne M. May
Anne M. May
HJHarriet Jager-Wittenaar
Harriet Jager-Wittenaar
CVCindy Veenhof
Cindy Veenhof
CSCaroline Speksnijder
Caroline Speksnijder
(1) Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) is associated with severe toxicity resulting in fatigue and weight loss, including loss of skeletal muscle mass. Exercise interventions might positively affect physical fitness and quality of life. Sufficient adherence and compliance rates are necessary for optimal effects. This study aimed to gain insight into expectations and experiences and factors influencing adherence, retention and compliance of HNC patients participating in exercise intervention during CRT. (2) Methods: Consecutive participants were invited for semi-structured interviews, conducted pre- and post-intervention. A deductive approach was used to identify themes and factors influencing adherence, retention and compliance. (3) Results: Thematic saturation was reached after interviewing 14 patients pre-intervention. Five themes were identified: planning and time management, treatment toxicity, motivation to exercise, exercise intervention and supervision by a physiotherapist. The intensity of the treatment schedule and treatment toxicity were important barriers. Facilitators mentioned were physical and emotional benefits, social support as well as the simplicity and home-based setting of the intervention. (4) Conclusions: A personalised approach, considering the individual facilitators and barriers of HNC patients, is important to increase adherence, retention and compliance to exercise intervention and to reap the optimal effects of the program.

12 October 2021 in European Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
AKAnnemieke Kok
Annemieke Kok
CLCarlijn Lugt
Carlijn Lugt
MLMarja J. Leermakers‐Vermeer
Marja J. Leermakers‐Vermeer
NRNicole M. Roos
Nicole M. Roos
CSCaroline Speksnijder
Caroline Speksnijder
Remco De BreeRemco De Bree
Remco De Bree
Objective To assess variations in nutritional interventions during chemoradiotherapy (CRT) among the Dutch Head and Neck Oncology centres (HNOCs). Methods An online questionnaire about nutritional interventions and dietetic practices was sent to 14 oncology dietitians of the HNOCs. Results The response rate was 93%. The number of scheduled dietetic consultations varied from two to seven during CRT. Most centres (77%) reported using a gastrostomy for tube feeding in the majority of patients. Gastrostomies were placed prophylactically upon indication (39%) or in all patients (15%), reactive (15%), or both (31%). For calculating energy requirements, 54% of the dietitians used the Food and Agriculture Organization/World Health Organization and United Nations University (FAO/WHO/UNU) formula and 77% uses 1.2–1.5 g/kg body weight for calculating protein requirements. Almost half of the centres (46%) reported to remove the gastrostomy between 8 and 12 weeks after CR. Most centres (92%) reported to end dietary treatment within 6 months after CRT. Conclusion This study shows substantial variation in dietetic practice, especially in the use of a gastrostomy for tube feeding, between the HNOCs. There is a need for concise dietetic guidelines.